nuplazid
FDA moots a return look at Acadia’s lead drug
April 27, 2018Medical Communications, Sales and Marketing Acacia, FDA, nuplazid, pharma
Following a non-profit report that higher rates of death were associated with Acadia Pharmaceuticals’ Nuplazid, Scott Gottlieb has made comments …
FDA says positives outweigh risks on Acadia’s Parkinson’s psychosis drug
March 30, 2016Research and Development, Sales and Marketing FDA, Parkinson's, Parkinsons, acadia, nuplazid, pimavanserin, psychosis
Acadia Pharmaceuticals (NASDAQ: ACAD) has announced a positive result from the US Food and Drug Administration (FDA) concerning Nuplazid (pimavanserin) …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
